Daratumumab in the Treatment of Relapsed/Refractory Multiple Myeloma: Real-World Experience from the Clinical Hematology Department of Avicenne Military Hospital, Marrakech
Abstract
Multiple myeloma (MM) is a malignant hematologic disorder characterized by clonal proliferation of tumor plasma cells. Treatment of MM has evolved over recent decades, improving progression-free survival (PFS) and overall survival (OS). Daratumumab has demonstrated superior efficacy when combined with other agents, with an acceptable safety profile. This retrospective study evaluates the efficacy and safety of daratumumab in 8 patients with relapsed/refractory MM. Results showed a treatment response in 75% of patients, with a 12-month progression-free survival of 75% and a 12-month overall survival of 87.5%. Daratumumab is an effective and well-tolerated treatment for patients with relapsed/refractory MM.
Fields of Study & Subjects
Multiple Myeloma Research and Treatments
Chronic Lymphocytic Leukemia Research
Monoclonal and Polyclonal Antibodies Research
Publication details
- Journal / source
- SAS Journal of Medicine
- Volume
- 12
- Issue
- 02
- Pages
- 125–127
- Publication date
- 19 February 2026
- Language
- EN